These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30667575)

  • 1. Laboratory assay measurement of modified clotting factor concentrates: a review of the literature and recommendations for practice.
    Young GA; Perry DJ;
    J Thromb Haemost; 2019 Apr; 17(4):567-573. PubMed ID: 30667575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
    Tiefenbacher S; Bohra R; Amiral J; Bowyer A; Kitchen S; Lochu A; Rosén S; Ezban M
    J Thromb Haemost; 2017 Oct; 15(10):1901-1912. PubMed ID: 28772338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement.
    Van den Bossche D; Peerlinck K; Jacquemin M
    Int J Lab Hematol; 2018 May; 40 Suppl 1():21-29. PubMed ID: 29741261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of recombinant coagulation factors in treating hemophilia.
    Morfini M; Rapisarda CAP
    Expert Opin Drug Saf; 2019 Feb; 18(2):75-85. PubMed ID: 30681006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.
    Kitchen S; Blakemore J; Friedman KD; Hart DP; Ko RH; Perry D; Platton S; Tan-Castillo D; Young G; Luddington RJ
    J Thromb Haemost; 2016 Apr; 14(4):757-64. PubMed ID: 26748742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
    Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
    Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays.
    Horn C; Négrier C; Kalina U; Seifert W; Friedman KD
    J Thromb Haemost; 2019 Jan; 17(1):138-148. PubMed ID: 30418692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies.
    Kitchen S; Tiefenbacher S; Gosselin R
    Semin Thromb Hemost; 2017 Apr; 43(3):331-337. PubMed ID: 28264199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia.
    Morfini M; Farrugia A
    Expert Rev Hematol; 2019 Oct; 12(10):883-892. PubMed ID: 31314609
    [No Abstract]   [Full Text] [Related]  

  • 10. Secondary prophylaxis with factor IX concentrates: continuous infusion.
    Morfini M
    Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s21-5. PubMed ID: 19105506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
    J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of pharmacologic options for the treatment of persons with hemophilia.
    Franchini M; Mannucci PM
    Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
    Mahdi AJ; Obaji SG; Collins PW
    Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?
    Björkman S
    Haemophilia; 2013 Nov; 19(6):882-6. PubMed ID: 24165155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
    Collins P; Chalmers E; Chowdary P; Keeling D; Mathias M; O'Donnell J; Pasi KJ; Rangarajan S; Thomas A
    Haemophilia; 2016 Jul; 22(4):487-98. PubMed ID: 27311929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A.
    Castaman G; Linari S
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):143-151. PubMed ID: 29257899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended half-life clotting factor concentrates: results from published clinical trials.
    Young G; Mahlangu JN
    Haemophilia; 2016 Jul; 22 Suppl 5():25-30. PubMed ID: 27405672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Half-life extension technologies for haemostatic agents.
    Mannucci PM
    Thromb Haemost; 2015 Jan; 113(1):165-76. PubMed ID: 25274414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study.
    Berntorp E
    Haemophilia; 2013 Nov; 19(6):805-7. PubMed ID: 24165154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in the treatment of bleeding disorders.
    Bergman GE
    Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.